TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases
Standard
TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. / Ghoreschi, Kamran; Augustin, Matthias; Baraliakos, Xenofon; Krönke, Gerhard; Schneider, Matthias; Schreiber, Stefan; Schulze-Koops, Hendrik; Zeißig, Sebastian; Thaçi, Diamant.
in: J DTSCH DERMATOL GES, Jahrgang 19, Nr. 10, 10.2021, S. 1409-1420.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases
AU - Ghoreschi, Kamran
AU - Augustin, Matthias
AU - Baraliakos, Xenofon
AU - Krönke, Gerhard
AU - Schneider, Matthias
AU - Schreiber, Stefan
AU - Schulze-Koops, Hendrik
AU - Zeißig, Sebastian
AU - Thaçi, Diamant
N1 - © 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
PY - 2021/10
Y1 - 2021/10
N2 - Immune-mediated chronic inflammatory diseases have emerged as a leading cause of morbidity and mortality in Western countries over the last decades. Although multiple putative factors have been suspected to be causally related to the diseases, their overarching etiology remains unknown. This review article summarizes the current state of scientific knowledge and understanding of the role of non-receptor tyrosine kinases, with a special focus on the Janus kinase TYK2 in autoimmune and immune mediated diseases as well as on the clinical properties of its inhibition. A panel of experts in the field discussed the scientific evidence and molecular rationale for TYK2 inhibition and its clinical application. Reviewing this meeting, we aim at providing an integrated overview of the clinical profile of TYK2 inhibition and its potential in targeted pharmacological therapy of chronic autoimmune and immune-mediated diseases, with a special focus on inflammatory diseases of the skin.
AB - Immune-mediated chronic inflammatory diseases have emerged as a leading cause of morbidity and mortality in Western countries over the last decades. Although multiple putative factors have been suspected to be causally related to the diseases, their overarching etiology remains unknown. This review article summarizes the current state of scientific knowledge and understanding of the role of non-receptor tyrosine kinases, with a special focus on the Janus kinase TYK2 in autoimmune and immune mediated diseases as well as on the clinical properties of its inhibition. A panel of experts in the field discussed the scientific evidence and molecular rationale for TYK2 inhibition and its clinical application. Reviewing this meeting, we aim at providing an integrated overview of the clinical profile of TYK2 inhibition and its potential in targeted pharmacological therapy of chronic autoimmune and immune-mediated diseases, with a special focus on inflammatory diseases of the skin.
KW - Autoimmune Diseases/drug therapy
KW - Humans
KW - Immune System Diseases/drug therapy
KW - TYK2 Kinase
U2 - 10.1111/ddg.14585
DO - 10.1111/ddg.14585
M3 - SCORING: Review article
C2 - 34580985
VL - 19
SP - 1409
EP - 1420
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 10
ER -
